METHODS
All regional genetics services in the UK were invited to participate. Procedures were explained at a training workshop to help ensure good compliance. Ethical approval was obtained through the Multicentre Research Ethics Committee. During a pre-specified 4-week period cancer genetic activity in all participating centres was logged. Designated staff-members at each centre completed report forms for every referral received, every individual attending, every telephone consultation and every cancellation/did-not-attend. Only activity relating to subjects under the age of 18 was excluded from the study. Information was requested about types of cancer/syndrome, source of and reason for referral, content of consulation and risk management plan for the individual. In addition, the lead consultant at each study centre was asked to supply general information about their service, such as catchment population size, frequency of clinics and details of staffing. Clinic attendees gave written informed consent and were asked to complete a questionnaire to provide mainly sociodemographic information.
We tested to see if the variability observed between regions could have occurred by chance. The Kruskal-Wallis test was used for waiting time and χ 2 test for all other comparisons.
RESULTS
22 of 24 regional genetics services agreed to participate. The catchment area of the participating centres covered the whole of Scotland, Wales and Northern Ireland and most of England, varying by region from 0.5 to 5.2 million population. These regional genetics services see individuals with a family history of cancer in a total of 141 hospitals. 53 of these hospitals held clinics specifically for familial cancer. 58% of new-attendee consultations were held in these designated cancer genetics clinics, 25% were in general genetics clinics and the remaining 17% were in other hospital clinics (e.g. breast lump diagnostic clinics). In the absence of facilities specifically for cancer families, there were 2 regions where all attendees were seen in general genetics clinics. In the other 20 centres the number of designated cancer genetics clinics provided per month ranged from 3 to 16 with a mean of 7.5. The regions also varied according to whether they provided cancer screening (e.g. mammography) directly (3/22) or else referred on or left the clinical management decision with the general practitioner. There was also variability in the use of family history questionnaires as part of the referral process. 7 centres sent questionnaires to more than two thirds of referred individuals before deciding whether to offer an appointment. One would expect these centres to be seeing proportionately fewer people than those centres with less restrictive appointment criteria.
12 of the 22 lead clinicians from the centres were aware of other cancer family history clinics within the region but outside of their jurisdiction. They specified 13 such clinics organized by breast screening units, 14 by breast surgeons and 2 by bowel surgeons, although these may represent the tip of the iceberg. In Scotland the clinicians reported that almost all family history clinics were organized by the regional genetics service.
Staffing of centres
In total there were 17 whole-time equivalent (WTE) consultants for a total catchment population of 53 million, consisting of 11 'dedicated' cancer genetics consultants (those spending more than 50% of their working time on cancer genetics) and another 46 consultants (mainly clinical geneticists) allocating less time. This amounts to 0.3 WTE consultants, or 0.2 'dedicated' consultants, per million of population. There were another 5 'dedicated' cancer genetics clinicians below consultant grade and 33 genetic counsellors (clinical nurse specialists, genetic associates, etc.). Therefore only half of the centres had a 'dedicated' cancer genetics consultant and 6 had no such dedicated staff at all, including the one with the largest catchment population. Table 1 shows the activity levels of the 22 regional centres combined. Referrals came equally from GPs (49%) and hospital clinicians (47%) with a few self-referrals. Table 2 shows the breakdown of referrals by gender and cancer site. The mean age of referrals was 41 years (SD = 11.5). Only 3% of attendees reported an ethnicity other than 'white' and almost half of these were 'Jewish' (a group known to be at greater genetic risk of breast cancer (Warner et al, 1999) ).
Activity levels and case-mix
Of the new-attendee consultations, 17% of attendees had previously been diagnosed with cancer (i.e. were 'affected'). Clinicians were asked to assign new attendees to one of 3 risk level categories -in some cases this was imprecise because the clinician was waiting for additional information before making the final clinical management decision. One quarter of clinic attendees (26%) were categorized as 'population level cancer risk or marginally above'. 49% were categorized as 'risk level sufficient for screening' and the remaining 25% was placed in the highest risk category. 
Risk management
74% of attendees at marginal risk were to be discharged without follow-up compared with only 12% and 5% in the middle and upper risk categories respectively. 25% of the middle risk group and 30% of the high-risk group would be referred on to another specialist. Many of these onward referrals, 50%, were for screening (mammography, clinical breast examination, endoscopy, etc.), a few were clearly for prophylactic surgery (mastectomy, colectomy, etc.) but for the rest it was not clear whether the referral was for screening, surgery or some other purpose. Cancer screening would be recommended for 97% of moderately increased and high-risk individuals (continued for 47% and initiated for 50%). For those at population risk 13% of familial breast cancer cases and 44% of familial bowel cancer were already being screened and for these the recommendation would be to discontinue screening. Prophylactic surgery would be discussed with 30% of individuals estimated to be at high-risk of breast cancer and 19% of those at high risk of bowel cancer. Clinicians indicated that they would consider molecular genetic testing for 63% of high-risk individuals and 24% of those at moderate risk. The number of tests actually carried out would be much smaller because of supply constraints and because many individuals decide not to go ahead with testing after counselling (Peshkin and Lerman, 1999) . Table 3 shows variations in activity between the regional cancer genetics services. Referral rates per million population varied significantly across the regions (P < 0.001) with a 5-fold difference at the extreme. Likewise, there was an 8-fold difference in the number of consultations with new attendees per million population across the region (P < 0.001). Referral rates were 53% higher in those centres providing mammography directly (P < 0.001) and 75% higher in those centres with a 'dedicated' cancer genetics consultant (P < 0.001). The 2 centres without familial cancer clinics had a 24% lower referral rate (P < 0.043). Referral rates were 40% higher in those centres with the most extensive use of pre-appointment questionnaires (P < 0.001), but they saw only 73% of referrals compared with 90% in the other centres. The proportion of a centre's referrals coming from primary care varied from 27% to 70% (P < 0.001).
Regional variations
There was a 13-fold difference in median waiting time across centres (range: 4-53 weeks; P < 0.001) (Table 3) , but no significant difference in waiting time between high-risk and population-risk subjects. Neither the use of questionnaire-based referral systems nor the availability of specialist cancer genetics staff appeared to affect waiting time but median waiting time was 5 weeks longer (22 weeks) for the 3 centres that provided screening directly (P < 0.001). The proportions of attendees at different risk levels varied significantly (P < 0.001), with the proportion at population level risk ranging from 0 (two centres) to 58%. As GPs referred more individuals at population-risk than did hospital clinicians (29% cf 18%, P < 0.001), the variations in casemix between centres are partly explained by the variations in the source of referrals. Centres with questionnaire-based referral systems seemed to be seeing the same proportion of population-risk individuals as other centres. The same was true for those centres with a dedicated cancer genetics consultant.
The proportion of those at elevated risk who were offered genetic testing varied from 0 (2 Scottish centres) to 80% across the regions (P < 0.001) but the advice on screening (whether to initiate, avoid, continue or discontinue) did not differ significantly. Testing and screening were no more likely in centres with a dedicated cancer genetics consultant or in those that provide screening directly or in those without designated cancer genetics clinics. 'Followup' rates depended on screening strategy. The 3 centres providing mammography directly accounted for two thirds of all contacts with returning attendees.
Figures for the 4 Scottish centres combined are presented separately as the Scottish service model implies less restrictive referral criteria. There were almost twice as many referrals and consultations per million population in Scotland than in the rest of the UK. There were substantially more population-risk (33% c.f. 26%) and medium-risk individuals (54% c.f. 49%). The Scottish centres reported that genetic testing was only available for research purposes; consequently they reported that genetic testing would only be discussed with 10% of individuals at medium risk or above compared with 73% in the rest of the UK.
DISCUSSION

Access to cancer genetics services
All of the UK regional clinical genetics services deal with individuals with a family history of cancer and only 2 of the 22 regions surveyed did not have designated cancer genetics clinics. Many of these services have developed intensively over recent years and service provision compares favourably with that reported for the USA 4 years earlier (Thompson et al, 1995) .
There is considerable variation in the resources and output of these services. The numbers of individuals referred were proportionately greater in those regions with a 'dedicated' cancer geneticist, direct provision of screening or questionnaire-based referral systems. Across the UK there was an 8-fold difference in the number of individuals seen as a proportion of catchment population and a 13-fold difference in waiting time, suggesting regional inequity of access. For high-risk families, those with a pattern of cancer in their family indicating Mendelian inheritance, access to the clinical genetics service is a greater priority since molecular testing in this group is more likely to find a genetic mutation. This would allow individuals at very high risk to be distinguished from relatives at much lower risk enabling more specific management. There were too few individuals at high-risk in this sample to effectively analyse regional equity of access for this subgroup. However, when this group is combined with those at moderate risk there is strong evidence of regional inequality of access to a specialist cancer genetics consultant and to genetic testing. There was no evidence of variation in screening recommendations, however this is somewhat tautological given that the moderate risk category was defined in relation to its need for screening. More important in terms of access is the supply of screening for genetically high-risk individuals, which in all but three regions is down to the individual policies of the local screening units and surgical departments.
A striking feature of the study was that referrals to and consultations at cancer genetics services overwhelmingly involve women and in particular those with a family history of breast cancer. This is partly explained by the prevalence of familial breast cancer in the population but must also be due to the publicity given to the breast cancer gene and to the interest in familial cancer shown by breast clinicians and geneticists over the last 2 decades. However, even within cancers that are not gender-specific, such as colon cancer, the number of women attending far outweighs the men. It is often thought that men generally under-use health services relative to women but the evidence is unclear (Moynihan, 1998) . Women are sometimes described as the 'guardians of family health'. The extent to which relevant genetic risk information will be passed on to other family members who may be at risk is not known. We observed, however, that only 35% of women (and 58% of men) reported that one of the reasons for attending was to find out the risk of other family members. Ethnic minorities also seem to be under-represented. The breakdown by gender and cancer site is remarkably similar to that of France (Sobol et al, 1999) and comparable with other European services (Hodgson et al, 1999) . However, there was a much larger proportion of affecteds in France, as a result of cancer genetics being carried out by cancer centres rather than genetics centres. Cancer genetic activity in France (2500 new cases each year) was barely a quarter of our estimate for the UK (Table 1) .
Achievement of service guidelines
There are few doctors who specialize in cancer genetics. According to the Harper Report recommendations, there should be at least 27 dedicated cancer genetics consultants for the population covered in this study, compared with the 11 observed. This situation is unlikely to change in the near future, as there is little training available for clinical oncologists to develop expertise in genetic counselling and no new posts opening up in clinical genetics to meet this need.
The report also recommended that moderate-risk cases should usually be managed in the cancer units and primarily high-risk cases should be referred to the specialist genetics service. The proportion of population-risk cases attending the regional cancer genetics service ranged from 0 to 58% implying that the model has not yet been fully adopted. The extent to which population-level and moderate-risk individuals are dealt with in cancer units and primary care must vary between regions. However, we cannot be sure that individuals encountering these services are being managed optimally, given that most of these services are not, as yet, under the guidance of the specialist cancer genetics service, as envisaged by the Harper Report.
Evidence from The Netherlands suggests that cancer genetics practised in primary care may be less than optimal (de Bock et al, 2001) , however, research-based initiatives are underway to educate primary care staff and facilitate liaison between the genetics services, cancer units and primary care and to reduce unnecessary referrals. These include the use of computerized risk assessment (Emery et al, 1999 (Emery et al, , 2000 or questionnaire-based family history assessment (Leggatt et al, 1999) by primary care teams. In several genetics services there are initiatives to train cancer unit nurses in genetic risk assessment and counselling. This will be strengthened with the proposed introduction of Macmillan funded posts into cancer genetic counselling.
Scotland appears to be closer to meeting the structure of its planned service model. There are few family history clinics outside of the regional genetics service. Consequently these services have more attendees than their English counterparts and proportionately more population-level and moderate-risk individuals. Of course, around the UK achievement of model guidelines may have improved since the survey was conducted.
Appropriateness of service guidelines
The Scottish Office model emphasizes the importance of a central referral system for all potential cases of familial cancer and access to genetic counsellors for individuals at lower levels of risk. This is a more comprehensive but potentially more costly approach than that proposed by the Harper Report where population-level risk individuals are dealt with mainly in primary care and those at moderately elevated risk in the cancer unit. A recent clinical trial (Brain et al, 2000) has shown that multi-disciplinary genetics teams were no more effective than breast surgeons at managing cases of familial breast cancer, when effectiveness was measured in terms of psychosocial outcomes. This would suggest that the Scottish model is unnecessarily reliant on the clinical genetics service although it may not be possible to generalize the results of Brain et al's study to other regions. Furthermore, Brain et al may have underestimated the extent to which inappropriate resource allocation occurs when clinical genetics is not utilized. Some centres in our study were re-evaluating individuals whose risk has previously been overestimated by nonspecialists. We found that, across all regions, the geneticists were recommending that screening be discontinued for 19% of population-level risk individuals (and be avoided for the rest of this risk group).
Regardless of which service model is followed, it is important that there is cohesion between the clinical genetics service, cancer units and primary care and, at the time of this study, this seems to be more evident in Scotland than in the rest of the UK.
Conclusions
The discovery of genes that cause elevated risk of cancer has lead to a substantial increase in the number of individuals being identified as having a 'genetic disorder'. This has established a workload, which is beyond the capacity of the UK regional genetics services. In the short term at least, most of these individuals must be dealt with by other sectors of the health service but to ensure appropriate clinical management this should be under the guidance of specialist cancer geneticists. The lack of cohesion between clinical cancer genetics and other cancer services is more evident in England and Wales than in Scotland. Initiatives to disseminate referral and management guidelines to cancer units and primary care should be encouraged and adequately resources so that clinical genetics teams can focus on genetic testing and management of high-risk families.
